Participated · Series B · Dec 2025

Sanegene Bio is a biotechnology firm focused on creating RNA interference (RNAi) medicines that target metabolic, cardiovascular, and autoimmune disorders. Its proprietary delivery platform is aimed at improving the clinical utility of RNA-based therapeutics, an area that is experiencing heightened global momentum. The company plans to use its latest capital infusion to advance multiple RNAi programs into registration studies, signaling a move toward late-stage clinical development. Management also intends to broaden the pipeline into additional disease areas within its core therapeutic focus. Although specific revenue or patient enrollment figures were not disclosed, the sizable financing underscores investor confidence in Sanegene Bio’s approach and delivery technology. With substantial strategic backing from industry leaders such as Eli Lilly and repeat participation from prior investors, the company is positioned to accelerate development and expand partnership opportunities.

Participated · Series A · Nov 2025

Founded in 2022, Phrontline Biopharma focuses on creating bispecific antibody ADCs (BsAb-ADCs) and dual-payload ADCs that combine two tumor targets and complementary cytotoxic payloads. The company has built an end-to-end platform covering antibody discovery, linker-payload engineering, site-specific conjugation, and functional characterization, giving it a proprietary technology engine for differentiated ADCs. Leveraging this platform, Phrontline has advanced nearly ten ADC programs, including its lead candidate TJ101, an EGFR/B7-H3 bispecific ADC now in first-in-human trials in China and the United States. Early preclinical data show TJ101 delivers superior efficacy and safety relative to peer programs. To accelerate development, Phrontline signed a global co-development pact with Samsung Bioepis for two bispecific, dual-payload ADCs and licensed China rights to TJ101 to Sino Biopharmaceutical in exchange for upfront, milestone, and royalty payments. The firm intends to use new capital to expand global clinical operations, strengthen strategic partnerships, and progress both clinical-stage and preclinical assets. No revenue or patient outcome metrics have been disclosed to date.

Led · Series C · Oct 2024

LaNova Medicines, founded in September 2019 and based in Shanghai, is a privately held clinical-stage biotech developing ADCs, bispecifics and monoclonal antibodies. Its pipeline includes six clinical-stage assets and more than ten preclinical programs, led by LM-302 (anti‑CLDN18.2 ADC), LM-108 (anti‑CCR8 mAb) and LM-299 (anti‑PD‑1/VEGF bispecific). LM-299 has entered a Phase I trial in China and LaNova expects to submit a U.S. IND in H2 2024. LM-302 is in a Phase III registrational trial in China with a planned U.S. Phase II start in H2 2025; LM-108 is in Phase II in China with planned U.S. Phase II and China Phase III milestones in H2 2024. The company emphasizes differentiated platform technologies for challenging targets and intends to advance its late-stage clinical programs toward registrational milestones. Recent financing proceeds will be used primarily to advance clinical development across the pipeline. LaNova Medicines completed a Series A financing in November 2020. The financing was led by Qiming Venture Partners, with China Renaissance acting as financial adviser. The announcement names additional investors including TF Capital, Yingke PE, Hony Capital, Biotrack Capital and YF Capital, among others. The article does not provide details on the company's product offerings, future plans, or operating metrics. The size of the Series A was not disclosed in the announcement. The announcement highlights Qiming Venture Partners' reputation, describing it as a top-tier VC firm with global recognition.

Led · Series A · Aug 2022

HanchorBio is a biotechnology company focused on immuno-oncology that develops proprietary Fc-based designer biologics (FBDB™) with multi-targeting modalities. Founded in December 2020, the company operates out of Taipei, Shanghai, and San Francisco and is led by industry veterans experienced in biologics discovery and global development. Its FBDB™ platform aims to reactivate innate and adaptive immune systems to kill tumors through multifunctional molecular configurations. HanchorBio reported promising in-vivo data from multiple tumor animal models across several projects. The company intends to use new financing to advance its growing pipeline, support IND-enabling GLP toxicology studies and IND submissions, and fund the first part of Phase 1 clinical trials. Management emphasizes improvements in R&D methodologies and CMC process development to translate novel biologics into transformative therapies.

Participated · Series D · Aug 2021

XtalPi develops an ID4 (Intelligent Digital Drug Discovery and Development) platform that combines computational physics, quantum chemistry, and cloud computing to predict key characteristics of new drug candidates. The platform measures various chemical indicators to enhance drug R&D efficiency and has enabled hundreds of pharmaceutical companies to accelerate their research pipelines. According to the articles, ID4's work has led to dozens of discoveries. Financially, XtalPi completed a $400 million Series D in August 2021 led by OrbiMed and RRJ, following a $300 million Series C less than a year earlier. The Series D brought XtalPi's valuation to over RMB 13 billion (approximately USD 2 billion). XtalPi develops an AI‑powered platform that combines atomic‑level physics simulation with data science to predict and prioritize drug‑like molecules. The company works with major pharmaceutical partners, including Pfizer, to identify promising targets and reduce dead ends in R&D. Its technology emphasizes extremely low‑level simulation and prediction alongside more traditional machine‑learning approaches. XtalPi requires significant scientific staff and facilities to validate and advance digital predictions into real‑world candidates. The firm positions its platform as a way to improve research efficiency and success rates across drug discovery, though the broader field has not yet delivered prominent breakthroughs. XtalPi was founded in 2014 and is described as an American‑Chinese biotech operation. XtalPi develops computation-driven drug discovery and development applications that integrate quantum physics, artificial intelligence and cloud computing to predict important drug properties of small molecules. Its core products are computational tools intended to accelerate and de-risk pharmaceutical innovations. The company plans to use the new funds to support continuous market growth and expand application of its technology into new areas of pharmaceutical research. XtalPi was founded in 2014 by a group of quantum physicists at MIT and is based in Cambridge, Mass. To date it has raised over $66m. The business combines physics-driven models with AI to target pharmaceutical research workflows. XtalPi builds computational tools that predict the crystal structures of drug molecules to inform stability and other properties that affect clinical success. The company combines AI, quantum-physics algorithms and high-performance cloud computing to improve the efficiency and accuracy of drug design, and it also works on drug discovery. XtalPi has built an elastic HPC cloud that can deploy up to one million cores across AWS, Tencent Cloud, Google Cloud and Alibaba Cloud. Founded in 2014 by three Chinese MIT graduates, it operates offices in Cambridge, Beijing and Shenzhen and has about 60 employees. The company plans to use big data from its high-precision computing platform to develop new computational models and to expand into new segments of the pharma industry. It is also developing a "prediction-driven research lab" that will combine its computational R&D with lab technology to produce more precise results and predictions.